# ALPN-101 (Acazicolcept) in Systemic Lupus Erythematosus

> **NCT04835441** · PHASE2 · COMPLETED · sponsor: **Alpine Immune Sciences Inc, A Subsidiary of Vertex** · enrollment: 76 (actual)

## Conditions studied

- Systemic Lupus Erythematosus

## Interventions

- **DRUG:** ALPN-101
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04835441
- **Lead sponsor:** Alpine Immune Sciences Inc, A Subsidiary of Vertex
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-06-22
- **Primary completion:** 2024-07-09
- **Final completion:** 2024-07-09
- **Target enrollment:** 76 (ACTUAL)
- **Last updated:** 2025-08-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04835441

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04835441, "ALPN-101 (Acazicolcept) in Systemic Lupus Erythematosus". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04835441. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*